Carbidopa: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== Function == | == Function == | ||
<StructureSection load='1js3' size='340' side='right' caption='Crystal structure of DOPA Decarboxylase in complex with the inhibitor carbidopa PDB:[[1js3]]' scene=''><scene name='pdbligand=142:CARBIDOPA'>Carbidopa</scene> (Lodosyn) is a drug given, in conjunction with Levadopa, to those with Parkinson's Disease in order to inhibit the peripheral metabolism of Levadopa, allowing a greater portion of the drug to cross the blood-brain barrier and produce the desired effect on the central nervous system. It works by inhibiting the enzymatic activity of aromatic-L-amino-acid decarboxylase ([[DOPA Decarboxylase]] or DDC)<ref name="one">PMID:11106255</ref> | <StructureSection load='1js3'=size='340' side='right' caption='Crystal structure of DOPA Decarboxylase in complex with the inhibitor carbidopa PDB:[[1js3]]' scene=''><scene name='pdbligand=142:CARBIDOPA'>Carbidopa</scene> (Lodosyn) is a drug given, in conjunction with Levadopa, to those with Parkinson's Disease in order to inhibit the peripheral metabolism of Levadopa, allowing a greater portion of the drug to cross the blood-brain barrier and produce the desired effect on the central nervous system. It works by inhibiting the enzymatic activity of aromatic-L-amino-acid decarboxylase ([[DOPA Decarboxylase]] or DDC)<ref name="one">PMID:11106255</ref> | ||
== Structure == | == Structure == | ||